Heart Failure Clinical Trials in Nashville, Tennessee

10 studies are recruiting for heart failure in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Nashville, Tennessee

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Nashville, TN Investigative Site 10071, Nashville, Tennessee

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

3. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

4. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

5. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Nashville, Tennessee

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

6. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

   This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

   Stage

   Phase 2

   Ages

   40 to 84

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   117 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06979362 on ClinicalTrials.gov

7. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

   This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt, Nashville, Tennessee

   Locations

   48 in total

   Run by

   Endotronix, Inc.

   See if you can join NCT05934487 on ClinicalTrials.gov

8. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

   The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Centennial Medical Center, Nashville, Tennessee

   Locations

   92 in total

   Run by

   Cardiac Dimensions, Inc.

   See if you can join NCT03142152 on ClinicalTrials.gov

9. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

   The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   14 in total

   Run by

   XVIVO Perfusion

   See if you can join NCT06895070 on ClinicalTrials.gov

10. AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

    Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.

    Stage

    Not phased

    Ages

    22 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    45 in total

    Run by

    Cordio Medical

    See if you can join NCT06378632 on ClinicalTrials.gov